Retinal artery occlusion

Summary

Retinal artery occlusion (MONDO:0006948) is a disease and 14 clinical trials. Top therapeutic interventions include regadenoson anhydrous and aspirin. A subtype of retinal vascular occlusion — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 14

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	retinal artery occlusion
Mondo ID	MONDO:0006948
EFO	EFO:1001154
MeSH	D015356
DOID	DOID:8483
NCIT	C34978
SNOMED CT	232035005
UMLS	C0035302
MedGen	11208
MedDRA	10038827
Is cancer (heuristic)	no

Disease family

This is a subtype of retinal vascular occlusion. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › retinal disorder › retinal vascular disorder › retinal vascular occlusion › retinal artery occlusion

Related subtypes (1): retinal vein occlusion

Subtypes (4): branch retinal artery occlusion, central retinal artery occlusion, partial arterial retinal occlusion, transient retinal arterial occlusion

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 3 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Alteplase	Phase 3 (in late-stage trials)
Aspirin	Phase 3 (in late-stage trials)
Tenecteplase	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Regadenoson Anhydrous.

Clinical trials & evidence

Clinical trials

Clinical trials: 14.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	12
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00637468	PHASE3	TERMINATED	EAGLE - Multicenter Study of the European Assessment Group for Lysis in the Eye
NCT03090087	PHASE2	UNKNOWN	The Effect of A2A Adrenoceptor Stimulation on the Diameter of Retinal Arterioles During Hypoxia in Vivo
NCT02141308	Not specified	RECRUITING	OCT in Rare Chorioretinal Diseases
NCT07482228	Not specified	RECRUITING	Long-term Clinical Outcomes After Retinal Artery Occlusion
NCT00804102	Not specified	COMPLETED	Transcorneal Electrical Stimulation Therapy for Retinal Disease
NCT01717937	Not specified	TERMINATED	Comparison of Phase-variance Optical Coherence Tomography and Fluorescein Angiography in Retinovascular Imaging
NCT02679716	Not specified	COMPLETED	Reconstruction of Pathological Changes of the Ophthalmic Artery in Patients With Retinal Artery Occlusion
NCT02806830	Not specified	COMPLETED	Ocular Discomfort Assessment After Intravitreal Injections
NCT02898480	Not specified	COMPLETED	Changes in the Diameter of Retinal Vessels After Remote Ischemic Conditioning
NCT03313817	Not specified	COMPLETED	Pre and Post-arterial Recanalization Imaging of Central Retinal Artery Occlusions (CRAO)
NCT03357146	Not specified	COMPLETED	Optical Coherence Tomography Angiography Examinations in Chronic Retinal Artery Occlusion
NCT03753893	Not specified	COMPLETED	Ocular Manifestations in Rheumatic Diseases
NCT04723160	Not specified	COMPLETED	Computer Aided Diagnosis of Multiple Eye Fundus Diseases From Color Fundus Photograph
NCT05130385	Not specified	UNKNOWN	High Resolution Optical Coherence Tomography

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
REGADENOSON ANHYDROUS	4	2
ASPIRIN	4	1
CHEMBL4303537	0	1